"2025 was a year that demonstrated Bambusa's execution-first culture," said Dr. Xu. "With multiple clinical programs advancing in parallel, we are entering 2026 positioned to deliver up to 10 clinical ...
BOSTON, Sept. 25, 2025 /PRNewswire/ -- Bambusa Therapeutics, Inc. (Bambusa Therapeutics), a clinical-stage biotechnology company pioneering next-generation bispecific antibodies for immunology and ...
BOSTON, Nov. 17, 2025 /PRNewswire/ -- Bambusa Therapeutics, Inc. ("Bambusa"), a clinical-stage biotechnology company pioneering next-generation bispecific antibodies for immunology and inflammation (I ...
BOSTON, Feb. 14, 2025 /PRNewswire/ -- Bambusa Therapeutics, Inc. (Bambusa), a biotechnology company developing bispecific antibodies for immunological and inflammatory (I&I) disorders, today announced ...
The first COPD patient has been dosed in a Phase 1b COPD trial testing Bambusa Therapeutics’ dual-target therapy BBT002.
Bambusa Therapeutics has raised about $90 million to build out a pipeline of next-gen bispecific antibodies targeting immunological and inflammatory (I&I) conditions. New investor RA Capital ...
BOSTON, May 30, 2025 /PRNewswire/ -- Bambusa Therapeutics, Inc. (Bambusa), a clinical-stage biotechnology company developing novel biologics for inflammatory and immunological diseases, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results